Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
Abstract
There remains an important need for prophylactic anti-Ebola virus vaccine candidates that elicit long-lasting immune responses and can be delivered to vulnerable populations that are unable to receive live-attenuated or viral vector vaccines.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 10, 2018
- Source ID
- 10.1093/infdis/jiy537
Entities
People
- Alexander Bello
- Amelia A Keaton
- Ami Patel
- Amir S Khan
- Daniel H. Park
- Daniel O Villarreal
- David B. Weiner
- Devon J. Shedlock
- Dinah Amante
- Emma L Reuschel
- Gary P. Kobinger
- Gary Wong
- Geoff Soule
- Jean Boyer
- Jewell Walters
- Jian Yan
- Jonathan Audet
- Kar Muthumani
- Kate E. Broderick
- Kaylie N Tran
- Kevin Tierney
- Kimberly A Kraynyak
- Marc-antoine De La Vega
- Megan C. Wise
- Niranjan Y. Sardesai
- Ross Plyler
- Shane Jones
- Shihua He
- Trina Racine
- Veronica L Scott
- Xiangguo Qiu
Organizations
- Defense Advanced Research Projects Agency
- Inovio Pharmaceuticals
- Laval University
- National Microbiology Laboratory
- University of Manitoba
- University of Pennsylvania
- William Carey University
- Wistar Institute